Freemont Management’s DexCom DXCM Stock Holding History

Freemont Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-45,700	Closed	-$3.12M	–	104
2025 Q1	$3.12M	Sell	45,700 -4,300	-9%	-$351K	1.03%	37
2024 Q4	$3.89M	Buy	+50,000	New	+$3.7M	1.69%	18

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Freemont Management's DXCM Position: Q1 2026 in Review

Freemont Management sold out of DexCom (DXCM) in Q1 2026, closing a stake of 17,800 shares — an estimated $1.18M sold.

Freemont Management first reported a position in DXCM in Q4 2022 and held it in 8 quarters. The position peaked at $20.9M in Q3 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Freemont Management reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
Freemont Management sold 17,800 DexCom shares in Q1 2026, an estimated $1.18M.
Freemont Management first reported a position in DexCom in Q4 2022 and held it in 8 quarters.
Freemont Management's DexCom position peaked at $20.9M in Q3 2023.
956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Freemont Management's 13F filing for Q1 2026, filed 6 May 2026.